Kornimate/medical-research-clean huggingface dataset:
regulation of inflammatory genes in hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: the purpose of this protocol is to examine the cytokine profi le of pati ents with hidradeniti s suppurati va (hs) and idemechanisms responsible for post-transcripti onal regulati on of these genes. the primary objecti ve is to determinfollowing cytokines linked to hidradeniti s suppurati va are diff erenti ally expressed in hidradeniti s pati ents versus controlalso doing a sub-study to determine the eff ect of childhood trauma on hs. the parti cipati on in the sub-study is opti onal

hidradeniti s suppurati va (hs) is a chronic infl ammatory cutaneous disease which involves the pilosebaceous-apocrwhich typically presents aft er puberty with painful nodules and abscesses which can form sinus tracts and scars in theapocrine gland-bearing sites of the body. 1 esti mates of disease prevalence range from 0.0003% to 4%, with youngparti cularly women as the most eff ected group. racial predilecti on has also been demonstrated, with a higher likeldisease in african american and biracial individuals when compared to whites.1 hs is an under-recognized enti ty, ontaking 7.2 years from symptom onset to formal diagnosis.2 a notable aspect of hs is the profound impact it can have oof life in pati ent's suff ering with the disease, with an increase in depression, pain, and social and work impairment.pathogenesis conti nues to be elucidated but is primarily thought to be due to follicular hyperkeratosis, leading formati on, dilati on, and rupture. this in turn causes infl ammati on, abscess and sinus tract formati on. 1, 4 whiunderstanding of a role of tumor necrosis factor (tnf) alpha, interleukin (il)-1, il-17a, il-23, c-reacti ve protein (cinterferon (ifn) gamma have been previously shown, much is sti ll unknown of the molecular involvement of infl ammarkers in hs.1, 2, 4. currently, management varies from topical treatment, to surgical excision, to prescribing manbiologic medicati ons used for hidradeniti s suppurati va and infl ammatory bowel disease. however, there can be vasvariability in response to these medicati ons, and a proper understanding of the infl ammatory markers involved inpathogenesis will allow for more specifi c treatment, while hopefully avoiding the adverse eff ects related to these isuppressive medicati ons. thus, in this study we will assess the cytokines, tnf-alpha, ifn-gamma, ifn-alpha, ifn-beta, iil-12, il-23, il-17a, and study their regulati on in hs lesions of pati ents, with the ulti mate goal of identi fying potenti al tafuture therapies and interventi ons.

Eligibility criteria:
inclusion criteria: * diagnosed with hidradenitis suppurativa * not pregnant exclusion criteria: * mild/general dermatological issues like moles, other cosmetic issues * patients with hidradenitis suppurativa, psoriasis, roasacea, atopic dermatitis and other inflammatory skin disease * pregnant
a european network for the investigation of gender incongruence

Conditions: Physical and Psychological Evaluation of Hormonal Therapy in Transsexual Persons

Summary: the physical and psychological effects of the hormonal treatment of transsexual persons are not sufficiently described. 'transparency' wants to answer this question in a prospective manner, in a multicenter study to describe these effects. the low prevalence of transsexualism was the stimulus to search for european partners for this protocol. a common standardized hormonal protocol was designed.


Eligibility criteria:
inclusion criteria: * transsexual persons older then 18 years, who are not yet treated with hormonal therapy. exclusion criteria: -
early cancer detection test - lung cancer scotland

Conditions: Lung Cancer

Summary: hypothesis in a high risk population the earlycdt-lung test reduces the incidence of late stage tumours;3 / 4 / unclassified (u) at diagnosis compared to normal clinical practice.

aims to assess the effectiveness of earlycdt-lung test in increasing early stage lung cancer detection, thereby reducing the rate of late stage (3 / 4 / u) presentation, compared to normal clinical practice; to assess the cost-effectiveness of earlycdt-lung test compared to normal clinical practice; to assess the effectiveness of earlycdt-lung test in reducing adverse outcomes including potential psychological and behavioural consequences.

Eligibility criteria:
inclusion criteria: 1. participant is willing and able to give informed consent for participation in the study 2. male or female aged 50 years to 75 years 3. current or ex-smoker with at least 20 year pack history 4. or less than 20 year pack history but with family history of lung cancer in a 1st degree relative (mother, father, sister, brother, child) 5. ecog status: 0, 1 and 2 (eastern co-operative oncology group) grade ecog 0 fully active, able to carry on all pre-disease performance without restriction 1 restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work 2 ambulatory and capable of all self-care but unable to carry out any work activities. up and about more than 50% of waking hours 6. geographical postal sectors of: nhs geographical area eligible postcodes tayside dd1 - dd11, ph1-ph3 , ph6-ph8, ph10, ph11, ph13, ph15 \& ph16 greater glasgow \& clyde g1-g5, g11 -g15, g20-g22, g31-34, g40 -g46, g51- g53, g60-g62 \&g64, g66 \& g69, g72 \& g73, g76-g78, g81-g83 pa1-pa8 (except pa6), pa11-pa16 \& pa19 exclusion criteria: 1. history of any cancer other than non-melanomatous skin cancer, cervical cancer in situ. 2. symptoms suggestive of lung cancer within past 6 months (haemoptysis, unintentional weight loss (at least 5% in preceding 6 months). 3. patients for whom the gp considers invitation to the study would cause undue distress. 4. patients with other terminal disease. 5. patients on prolonged / continuous use (\> 3months) of cytotoxic/ immuno-suppressant drugs eg: cyclophosphamide. monotherapy using glucocorticoids/ steroids eg prednisolone is not an exclusion criteria.
surgery outcome treated by neo-adjuvant combination of oxaliplatin, irinotecan, folinic acid and fluorouracil (folfoxiri) regimen in synchronous liver limited metastasis colorectal cancer

Conditions: Liver Metastasis Colon Cancer; Synchronous Neoplasm

Summary: this single arm study aims to evaluate the rate of conversion therapy in patients with unresectable liver-limited metastatic colorectal cancer (mcrc) using folfoxiri neoadjuvant regimen and to assess the other outcome including the response rate, the survival rate and the safety profile.

patients with liver-only metastases colorectal cancer could potentially be cured following surgical resection of metastases. recent evidence suggest that a triplet chemotherapy regimen, folfoxiri has been associated with higher r0 resection. eighty-nine eligible patients will be recruited at cho ray hospital in vietnam. patients will receive neoadjuvant folfoxiri regimen every two weeks for up to 12 cycles and will undergo periodic imaging studies. the resectability of liver metastases will be assessed by a multidisciplinary team comprised of digestive surgeons, hepato-biliary surgeons, radiologists, and oncologists. this study will be helpful to establish a standard chemotherapy regimen for patients with liver-limited metastatic colorectal cancer. moreover, this study will assess the surgical outcome, the response rate, the survival rate, the safety of triple drug chemotherapy and the association between conversion operable disease and various survival rate and patient's characteristics.

Eligibility criteria:
inclusion criteria: * patients from 18 to 75 years * able to give informed consent * have a histological adenocarcinoma diagnosis of colorectal cancer * resected or operable colorectal primary tumor * initially unresectable liver lesion considered by multidisciplinary team (mdt) * world health organisation performance status (ecog ps) 0, 1 * adequate complete blood count, liver and renal function exclusion criteria: * prior history of other active malignancies * unmeasurable lesion according to recist criteria v.1.1 * recurrence of colorectal cancer * resection or ablation of liver lesion * distant metastases outside the liver * patients who have received prior chemotherapy with oxaliplatin, irinotecan, capecitabine, 5-fluoro-uracil. * concomitant uncontrollable medical status ie. symptomatic cardiac disease, infarction within 24 months, uncontrollable cardiac dysrhythmia, active infectious disease * pathology of the liver lesion except adenocarcinoma metastasis from colorectal cancer.

Keywords: folfoxiri
allopurinol outcome study

Conditions: Gout

Summary: this is a study of allopurinol in gout patients with hyperuricemia that will evaluate the safety and serum urate (sua) lowering capability of allopurinol as a urate lowering therapy (ult) for up to six months. allopurinol will be dosed according to the local product label, at the discretion of the investigator, to achieve an optimal, medically appropriate dose for each patient.


Eligibility criteria:
inclusion criteria: * meets the diagnosis of gout according to the american rheumatism association (ara) criteria for the classification of acute arthritis of primary gout. * not on a urate lowering therapy (ult) must have an sua level ≥ 8.0 mg/dl at screening. * if on concomitant ult must have an sua level ≥ 6.5 mg/dl at screening. * must have had at least 2 gout flares in the past year. exclusion criteria: * consumption of more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz \[150 ml\] of wine, 12 oz \[360 ml\] of beer, or 1.5 oz \[45 ml\] of hard liquor). * history or suspicion of drug abuse. * history of autoimmune disease requiring systemic treatment. * known or suspected human immunodeficiency virus (hiv), hepatitis c antibody (hcv), or hepatitis b antibody (hbsag) infection. * history of malignancy within the previous 5 years (with the exception of nonmelanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia or treated in situ grade 1 cervical cancer). * myocardial infarction, unstable angina, new york heart association (nyha) class iii or iv heart failure, or stroke within the last 12 months. * uncontrolled hypertension (systolic pressure above 160 mm hg or diastolic pressure above 95 mm hg). * estimated creatinine clearance \< 30 ml/min by cockcroft-gault formula. * kidney or other organ transplant. * active peptic ulcer disease requiring treatment. * history of xanthinuria, active liver disease, or hepatic dysfunction. * if unable to take gout flare prophylaxis of either colchicine or nonsteroidal anti-inflammatory drugs (nsaids) due to contraindication (e.g. toxicity, renal function, use of contraindicated medications). * known hypersensitivity or allergy to allopurinol.
efficacy and safety of zoledronic acid for the treatment of osteoporosis in men

Conditions: Osteoporosis

Summary: the goal of this study is to determine the effectiveness and safety of an annual intravenous treatment of zoledronic acid for the treatment of osteoporosis in men. all patients will receive calcium and vitamin d supplements.


Eligibility criteria:
inclusion criteria: * male, 25-85 years old exclusion criteria: * current users of bisphosphonates such as aredia® (pamidronate), didronel® (etidronate), fosamax® (alendronate), actonel ® (residronate), skelid® (tiludronate) * history of severe liver, kidney or eye disease other protocol-defined inclusion/exclusion criteria may apply.

Keywords: male osteoporosis
evaluating the effectiveness of a headache management program in primary care settings

Conditions: Headache, Migraine; Headache

Summary: between january 2020 to august 2021, fifty percent of patients referred from geisinger's primary care sites to neurology for headaches did not trial appropriate first line therapy prior to referral, and there was limited access available at geisinger's neurology department. this project was initiated to improve patient experience, management of headache, and provider experience as it relates to headache management. geisinger's neurology department, pharmacy department, and community medicine service line (cmsl) sites have collaborated to develop a headache carepath (i.e., a best practice alert containing: an epic headache assessment, express lane for prescriptions, and ask-a-doc button for neurology consult) and piloted at 2 cmsl sites (woodbine, selinsgrove) to gain some initial feedback. the feedback has been incorporated into best practice alert (bpa) language and criteria. the project team now plans to implement this carepath to half of cmsl sites first while the other half of cmsl sites will continue to practice the standard of care as of today. the team will evaluate the impact of this carepath on patient outcomes \[change in headache impact test-6 (hit-6) scores, change in the frequency of headaches, and change in pain intensity\], emergency department (ed) visits, number of referrals to neurology for headache, and prescribing of headache medications by comparing the measures in clinics that had the carepath implemented to those that did not. patient outcomes will be collected by geisinger's survey core, which will reach out telephonically to patients to ask about the status of their headaches (hit-6, frequency, intensity of headaches, m-toq-5). other measures will be collected and analyzed using secondary data sources such as electronic health record (ehr) data. the initial implementation is planned for 6-9 months. the findings from this evaluation will help the carepath team identify any remaining opportunities or guide the direction of its future enhancements of the carepath tools. the results of this evaluation will be shared with the geisinger leadership to demonstrate its value to the organization.


Eligibility criteria:
inclusion criteria: * adult patients ≥ 18 years of age for whom the headache bpa fires at the time for their pcp encounter * new or returning patients with headache as visit diagnosis or chief complaint for the office visit or telemedicine encounter * have a minimum baseline hit-6 score of ≥ 50 points or * headache frequency of ≥ 12 days with headache or migraine complaint in the last 3 months exclusion criteria: * patients at the pilot sites (i.e., woodbine, selinsgrove) * patients diagnosed with secondary headache disorders (eg, brain tumors) or serious systemic illness (eg, uncontrolled hypertension, hepatic or renal failure, cardiac failure) or acute infectious illness (eg, flu, sinusitis). * patients with headaches as a symptom due to fall/injury * pregnant women

Keywords: clinical care evaluation primary care
falls and balance of patients with parkinson's disease with urinary disturbance

Conditions: Parkinson's Disease; Falls; Balance; Urinary Bladder Diseases

Summary: the aim of this study is to determine the fall and balance conditions of parkinson's patients according to their urinary complaints.

parkinson's disease (pd) is a slowly progressive and common neurodegenerative disease.frequently encountered problems in lower urinary tract complaints; bladder dysfunction, such as urinary entrapment and frequent urination.urinary incontinence in individuals with parkinson's disease increases the risk of falling. the investigators will evaluate 80 patients who attended the movement disorders outpatient clinic of ordu a university educational research hospital in december 2018 and february 2019, and were diagnosed as having parkinson's disease. other eligibility criteria for participants were having good cognitive functions (\>24 on standardized mini mental test) and were volunteers who accept to participate in the study. the investigators excluded patients that having orthopedic and / or neurological problem affecting walking and balance skills. the investigators used unified parkinson's disease rating scale (updrs), modified hoehn and yahr stage (h/y), berg balance scale (bbs), falls-efficacy scale (fes), timed up and go (tug), and five times sit to stand test (ftsts), iciq-sf and overactive bladder version-8.

Eligibility criteria:
inclusion criteria: * parkinson's disease according to the united kingdom brain bank diagnostic criteria * good cognitive functions (\>24 on standardized mini mental test) * volunteers who accept to participate in the study. exclusion criteria: * orthopedic and / or neurological problem affecting walking or balance skills * not willing to participate in the study
stroke rate in patients with blunt cerebrovascular injury (bcvi) treated with oral acetylsalicylic acid (asa) 81 mg versus asa 325 mg (basa).

Conditions: Blunt Cerebrovascular Injury

Summary: the goal of this clinical trial is to compare difference between aspirin 81 mg and aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. the main questions it aims to answer are: * if aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and aspirin 325 mg. * if rate of hemorrhagic complications in patients with head and neck vessels injury taking aspirin 81 mg is not higher than patients that take aspirin 325 mg.


Eligibility criteria:
inclusion criteria: * age ≥18 * all patients with blunt cerebrovascular injury are diagnosed by computed tomography angiography (cta) upon admission exclusion criteria: * age \<18 * pregnant women * no enteral route access for aspirin administration * patients who are on heparin drip or other full dose anticoagulation when bcvi diagnosed * patients who are on other anti-platelets aside from aspirin when bcvi diagnosed * patients with bcvi grade 5 injury based on biffl classification * presence of any contraindication or history of allergy to aspirin * patient with the diagnosis of acute stroke at the time of bcvi diagnosis matching the injured vessel territory on imaging * patients with acute spinal trauma that needs surgical intervention

Keywords: blunt cerebrovascular injury bcvi carotid artery vertebral artery internal carotid artery
ultrasonographic assessment of the effect of cpb acute lung injury

Conditions: Lung Ultrasound

Summary: the study is designed to use the lung ultrasound to assess the effect of intermittent lung recruitment during cardiopulmonary bypass in cardiac surgeries on extra vascular lung water.

significant respiratory dysfunction is a common problem after cardiac surgery, with an incidence of about 25%. the formation of atelectasis appears to be the primary factor responsible for increased intrapulmonary shunt after cardiac surgery with cpb. the investigators will use the lung ultrasound to evaluate the effects of intermittent recruitment of the lungs during cpb on extra vascular lung water (evlw). objectives : to evaluate the effect of intermittent lung recruitment during cpb in cardiac surgery on: lung ultrasound score (lus),oxygenation at different times postoperatively,time for extubation and length of icu stay sixty patients aged from 18-60 years old, scheduled for elective cardiac surgery with cpb will be included in the study. patients will be randomly allocated into one of two groups: group a (n=30): will receive intermittent lung recruitment during cpb.group b (n=30): control group.

Eligibility criteria:
inclusion criteria: * adult patients aged (18-60 years), * elective valvular cardiac surgery with cardiopulmonary bypass (cpb). exclusion criteria: * • emergency surgeries. * coronary artery bypass graft surgery * patients requiring re-exploration in the immediate postoperative period (within 2hours) * left ventricular ejection fraction less than 40% * patients with preoperative congestive heart failure, cardiogenic shock , preoperative pulmonary edema * pre-existing severe chronic pulmonary dysfunction (defined as pulmonary disease requiring home oxygen therapy or causing shortness of breath after 1 to 2 flights of stairs) * morbid obesity * renally impaired patients with creatinine more than 2 mg/dl
the effect of patient education and rehabilitation on quality of life in patients with permanent stomas

Conditions: Colostomy

Summary: the purpose of the experiment is to study the effect it has on patients' quality of life if they go through a structured process marked by intensified and specialized effort by ostomy nurse. this includes close monitoring during hospitalization, telephone contact and guidance following discharge and participation in a group based patient school up to 4 months after discharge . at the same time the study also examines what the economic effect of following the intervention will have.

construction of an ostomy is a radical treatment with permanent physical signs of body alteration. it leads to loss of a central and very personal bodily function (excretion of faeces through the rectum) and there is a significant change in personal hygiene. having a colostomy is not a uniform state but is characterized by many different factors: several types of ostomy, several underlying causes that lead to stoma creation such as cancer, several individual psychosocial profile, which naturally affect individuals differently. patients are forced to living with a changed body image, a change in daily routines, and for some there will also be changes in lifestyle, social standing and their sexuality will be affected. at the same time patients experience a break when they are discharged from the hospital, and they may lack the practical and emotional support. the training and education of patients is increasingly being carried out by stoma nurses both in denmark and internationally. the primary role is to inform and prepare patients before surgery and to keep the contact with patients after surgery to ensure the fulfillment of the patient´s independent and meaningful life after ostomy construction. it is assumed that ostomy nurse's intervention and involvement are important for the patient's quality of life, but there are no studies that uniquely identifies the type of education that has the greatest effect, which applies both to content and methods. quality of life measurement in health care is a merging method to ensure the patient´s perspective on health treatments.it is greatly needed to test the efficacy of nursing interventions on patients' quality of life. pressure on health services increase which makes it imperative also to include analysis and calculation of economic effect of the intervention.

Eligibility criteria:
inclusion criteria: * all patients with permanent or temporary stomas regardless of cause that are expected to be able to cooperate in filling out questionnaires and who will participate in the planned interventions. exclusion criteria: * patients that post-operatively are not able to cooperate and participate in the planned interventions.

Keywords: patient education health-related quality of life patients with stomas stomatherapy health economics